This site is intended for health professionals only
Tuesday 25 September 2018
Share |

Topic: Latest News

September 7, 2018

A ‘hard look’ at gender parity issues will be vital as the proportion of women working in pharmacy increases, a representative body for the sector has warned.
 

September 7, 2018

Pharmacists could do more to empower female carers, a representative body for the sector has urged.
 
A report published yesterday (3 September) by the International Pharmaceutical Federation (FIP) showed that pharmacists are in an ‘ideal position to empower’ informal women caregivers.
 
The news comes while the FIP holds its 78th annual World Congress of Pharmacy and Pharmaceutical Sciences in Glasgow, from 2 to 6 September.
 
‘Key’ relationship

September 7, 2018

Six in 10 pharmacy professionals are against the sale and dispensing of homeopathic products, pharmacists at an international conference have heard.

August 30, 2018

The European Commission has approved Vyxeos 44 mg/100mg powder for concentrate for solution for infusion for the treatment of adults with newly-diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes, manufacturer Jazz Pharmaceuticals has announced.
 
Vyxeos is an advanced liposomal formulation that delivers a synergistic molar ration of daunorubicin and cytarabine, Jazz Pharmaceuticals said.
 
The EC approval extends to all European member states as well as Iceland, Norway sand Liechtenstein.

August 30, 2018
The increasing number of tumour biomarkers being discovered, and the role of NGS in helping oncologists to make informed treatment decisions, is discussed

For decades, tissue-conserving surgery coupled with chemotherapy (either preceding or following surgery, depending on the size of the tumour(s)) followed by radiation has been the standard of care for the majority of cancers.

August 30, 2018

Novartis UK Oncology statement on Novartis receiving European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)

August 24, 2018

Kathy Oxtoby looks at the effects of antimicrobial resistance across Europe will be if it goes unchecked and investigates what should be done to tackle it
 
It may be a natural phenomenon, but antimicrobial resistance (AMR) has become a global health crisis of similar importance to infectious-disease pandemics, according to the World Health Organization (WHO).
 

August 24, 2018

Working as a pharmacist in the Central African Republic and the Democratic Republic of the Congo was a rewarding experience, despite considerable challenges, explains Barbara Pawulska
 
What with busy dispensaries and tricky patients to contend with, life as a pharmacist can present challenges in any walk of the profession.
 

August 14, 2018

Only one third of pharmaceutical companies are compliant with Europan anti-counterfeiting measures, according to a representative group.
 
In a letter sent last week (6 August), the European Medicines Verification Organisation (EMVO) said that of the 2,291 pharmaceutical companies that have to connect to the European Medicines Verification System (EMVS) in less than six months, only 841 (36%) have signed the required agreement. 
 

August 9, 2018

New restricted indications on prescribing Esmya (ulipristal acetate) for symptoms of uterine fibroids put in place by the UK’s medicines watchdog now replace instructions that the drug should not be prescribed to any new patients.
 

August 8, 2018
Senior clinicians will be able to legally prescribe cannabis-derived medicines this autumn, the Home Office has announced.

Senior clinicians will be able to legally prescribe cannabis-derived medicines this autumn, the UK's Home Office has announced.
 

August 6, 2018
New patient groups with cancer-associated venous thromboembolism (VTE) could benefit from taking once-daily oral LIXIANA (edoxaban), a recent analysis has said.

New patient groups with cancer-associated venous thromboembolism (VTE) could benefit from taking once-daily oral LIXIANA (edoxaban), a recent analysis has said.
 
Manufacturer Daiichi Sankyo announced today (6 July) it had published a new analysis on the clinical presentation, course and outcome of bleeding events in Thrombosis and Haemostasis, and the associated tumour types from the Hokusai-VTE cancer study.
 

August 2, 2018

The Government should consider the economic as well as health benefits of vaccinating people against flu, according to research by a think tank.
 
Research by the International Longevity Centre – UK (ILC-UK) argued that flu can adversely affect productivity within the economy. The biggest economic benefit of vaccinating against the condition is the reduction of lost employment and care giving costs, which total between £90m and £270m , it said.
 

July 26, 2018

Matt Hancock MP was appointed digital, culture, media and sport secretary in January 2018 having been a junior minister in the department since July 2016. He was first elected an MP in the 2010 general election in the West Suffolk constituency.
 
Before entering parliament, he worked as an economist at the Bank of England and as chief of staff to the shadow chancellor.
 
He has little health background, with no obvious links to the NHS.
 

July 26, 2018
How will Matt Hancock’s healthcare priorities benefit the NHS?

Last week, health and social care secretary Matt Hancock gave his first speech at West Suffolk Hospital where he revealed three key priorities for the NHS: technology, workforce and prevention.
 
Speaking before the Health and Social Care Committee yesterday, he also gave more information on the work he intends to do.
 
A version of this article first appeared on our sister publication Healthcare Leader
So what do the priorities mean for the health service?
 
Technology focus

July 19, 2018
Up to 42% of UK medicines may not be able to market their products in the European Union (EU) post-Brexit, a survey from the European Medicines Agency (EMA) has revealed.

Up to 42% of UK medicines may not be able to market their products in the European Union (EU) post-Brexit, a survey from the European Medicines Agency (EMA) has revealed.
 
The EMA said marketing authorisation holders for 58% of 693 centrally authorised products (CAPs) are on track to ensure they can continue to market their products once the UK leaves the EU in March 2019.
 

July 19, 2018
The UK’s National Health Service turned 70 this month, and while we celebrate the achievements of one of the nation’s most valuable institutions, it’s also the perfect opportunity to pinpoint the role that pharmacy has played in the NHS during those decades.

The role of pharmacists in the NHS has, unsurprisingly, evolved quite a bit since its inception. Growing from what was originally a supply service to become a clinical practice in hospitals, and with a range of new roles in primary care, pharmacists are now recognised as a valuable part of the multidisciplinary clinical team.
 

July 12, 2018
Point-of-care ultrasound is at the heart of Frimley Park Hospital’s anaesthesia department, guiding procedures such as vascular access and nerve blocks.

Point-of-care ultrasound is at the heart of Frimley Park Hospital’s anaesthesia department, guiding procedures such as vascular access and nerve blocks.
 

July 12, 2018
Patients with rare autoinflammatory diseases in the UK have a new treatment option with the launch of Sobi’s Kineret following approval from the European Medicines Agency (EMA) earlier this year.

Patients with rare autoinflammatory diseases in the UK have a new treatment option with the launch of Sobi’s Kineret following approval from the European Medicines Agency (EMA) earlier this year.
 
The drug is already licensed in the UK for treating rheumatoid arthritis and cryopyrin-associated periodic syndromes (CAPS). It will now be available to patients with adult onset stills disease (AOSD) and systemic-onset juvenile idiopathic arthritis (SIJA), which impacts children under the age of 16 years.
 

July 11, 2018
The drug will be now available for dose optimisation in UC patients with a body weight of less than 80kg, who do not respond to induction therapy.

The European Commission (EC) has approved a label change for Simponi (golumumab) allowing early dose optimisation in patients with ulcerative colitis (UC).
 
The drug will be now available for dose optimisation in UC patients with a body weight of less than 80kg, who do not respond to induction therapy.
 

July 10, 2018
In draft guidance published on 9 July NICE recommended that healthcare professionals prescribe antibiotics to people with COPD only when suffering from severe acute exacerbations

Antibiotics should be restricted when used for chronic obstructive pulmonary disease (COPD), the National Institute for Health and Care and Excellence (NICE) has urged.
 

July 5, 2018
Cimzia can be used for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, following label extension by European Medicines Agency (EMA)

The European Medicines Agency (EMA) has approved a label extension for Cimzia (certolizumab pegol) therapy, Belgian biopharmaceutical company UCB has announced.
 
The extension allows Cimzia’s use for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
 

July 4, 2018
A clinical trial to treat female diffuse hair loss has been kick started by US regenerative medicine company Histogen.

A clinical trial to treat female diffuse hair loss has been kick started by US regenerative medicine company Histogen.
 
This month [June 2 2018], the organisation announced the launch of a Phase I Clinical Trial of its lead product, Hair Stimulating Complex, to treat the condition.
 

July 2, 2018
The CHMP has given a positive opinion recommending Novartis’s Kymriah (tisagenlecleucel) to treat two aggressive blood cancers.

The Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending Novartis’s Kymriah (tisagenlecleucel) to treat two aggressive blood cancers.
 
The CHMP, which is part of the European Medicines Agency (EMA), gave a positive opinion on using tisagenlecleucel to treat B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-stem cell transplant or in second or later relapse in patients up to 25 years of age.